GLP-3RTA Spray

What Is GLP-3RTA?

GLP-3RTA is a synthetic peptide of 39 amino acids, catalogued under CAS 2381089-83-2 and originally developed under the code LY-3437943. The scientific literature describes it as a unimolecular triple receptor agonist: a single molecule engineered to activate the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

The “GLP-3” element of the designation is a catalog and media convention rather than a scientific classification, and it is worth being direct about that. No hormone called GLP-3 exists. The proglucagon precursor yields glucagon, GLP-1, GLP-2, glicentin and oxyntomodulin — there is no third glucagon-like peptide and no GLP-3 receptor. The compound’s pharmaceutical developer states this explicitly, describing “GLP-3” as a scientifically inaccurate label used informally in the media, arising because the molecule targets three receptors rather than because it denotes a real classification, and identifying “triple agonist” as the appropriate term. The “RTA” component has no established scientific meaning; researchers evaluating material under any catalog designation of this kind should confirm identity from the CAS number and the supplier’s analytical documentation rather than from the name.

The prefix is misleading in a second, more consequential way. This compound’s peptide backbone derives from the GIP sequence, not from GLP-1. And among its three targets, the highest reported in vitro potency is at GIPR — an EC₅₀ near 0.064 nM, against roughly 0.78 nM at GLP-1R and 5.8 nM at GCGR. Both the structural origin and the most potently engaged receptor point away from GLP-1, so a researcher selecting a reference ligand on the strength of the prefix would be reasoning from the wrong premise. For GIPR work in particular, that matters.

Structurally, the molecule carries three non-canonical residues that distinguish it from a straightforward native-sequence peptide: α-aminoisobutyric acid at position 2, which blocks DPP-4 cleavage at the N-terminus; α-methyl-leucine at position 13; and a second α-aminoisobutyric acid at position 20. A C20 fatty diacid is attached to a lysine side chain through a γ-glutamyl-(AEEA) linker, and the chain terminates in a serinamide. The lipid conjugation promotes albumin binding, which is the design feature underlying the long circulating half-life of roughly six days reported in human studies of the pharmaceutical formulation.

GLP-3RTA Spray as a Prepared Solution

The word “spray” describes the physical presentation of this material. It is a prepared solution in a spray-format container. It does not designate nasal, oral, sublingual, inhaled, topical or any other route, and Helix Bio does not supply this material for administration to humans or animals by any means. Worth noting alongside that: every published human study of this compound used subcutaneous injection of a pharmaceutical formulation.

What the solution format genuinely changes is handling chemistry. This molecule is unusual in the catalog for its size and construction: at roughly 4.7 kDa it is an order of magnitude larger than most peptides on this site, and the C20 diacid makes it an amphiphile — a large hydrophilic peptide chain carrying a substantial lipid tail. Amphiphilic peptides in dilute aqueous solution tend to accumulate at interfaces, so container-surface adsorption and air-liquid interface effects are more consequential here than for a small unmodified peptide, and self-association is a recognised behaviour of lipidated peptides generally.

None of that is a statement about this formulation. Vehicle composition, concentration, pH, ionic strength, the presence of any surfactant and the container material determine how those tendencies actually behave, and those are product facts belonging in the product documentation rather than inferences from the molecular class.

Research Context

GLP-3RTA appears in receptor pharmacology and metabolic research, including:

• Multi-receptor incretin signalling
• GIPR, GLP-1R and GCGR binding and functional assays
• Comparative studies of mono-, dual- and triple-receptor agonist design
• Structure–activity research on backbone-constrained peptide analogues
• Lipidated peptide chemistry and albumin-binding design
• Cellular models of receptor-mediated cAMP signalling
• Preclinical metabolic research models
• Analytical method development for large lipidated peptides

The existence of a substantial clinical development programme for this compound does not establish that a research material is safe or effective for any purpose. Those studies used a sponsor-manufactured pharmaceutical product administered by a defined route under clinical oversight, and their findings describe that product under those conditions.

• GLP-3RTA supplied as a prepared research solution in spray-format packaging
• Synthetic 39-residue lipidated peptide; unimolecular triple receptor agonist
• CAS 2381089-83-2; developed under the code LY-3437943
• Targets GIPR, GLP-1R and GCGR; highest reported in vitro potency at GIPR
• Backbone derived from the GIP sequence, not from GLP-1
• Non-canonical residues: Aib at positions 2 and 20, α-methyl-leucine at position 13
• C20 fatty diacid conjugated through a γGlu-(AEEA) linker; C-terminal serinamide
• “GLP-3” is a catalog and media convention, not a hormone classification
• Reported molecular mass varies between sources; confirm against lot documentation
• Supplied exclusively for research and laboratory purposes
• Investigational compound; not approved by any regulatory authority for any use

Two things make this material harder to characterise than most peptides in a research catalog, and both are worth knowing before a lot is accepted.

The first is size and construction. A 39-residue chain carrying a C20 fatty diacid behaves differently in a chromatographic system than a short unmodified peptide. Closely related impurities — deletion sequences, des-lipidated material, incompletely deprotected species — elute near the main peak, and a single area-percent figure compresses all of that into one number. The number is still worth having; it simply carries less information per digit than the same figure would on a seven-residue peptide, and the method behind it matters correspondingly more.

The second is mass basis. Published sources do not agree on this compound’s molecular formula and weight: the majority report C₂₂₁H₃₄₂N₄₆O₆₈ at approximately 4731 g/mol, while at least one reference resource reports a formula around 4895 g/mol, and several suppliers describe a sodium salt form. On a molecule of this size those differences are a few percent — small enough to pass unnoticed, large enough to matter to a concentration calculation. Anyone preparing a defined molar concentration should confirm which mass the documentation refers to, and whether stated content is expressed on a peptide or salt basis.

There is a third consideration specific to material sold under catalog designations. Because “GLP-3RTA” is a trade convention rather than a registry name, the CAS number is the anchor that ties a shipment to a defined molecular entity. Documentation that states the CAS number, the observed mass and the analytical method is doing something a product name cannot do on its own. Helix Bio states that its research materials are supported by batch-specific Certificates of Analysis and by HPLC and mass spectrometry testing; the applicable lot documentation, not this page, is the authoritative record of what a given container holds.

GLP-3RTA Spray is intended for qualified users working in legitimate laboratory or scientific research environments, including:

• Receptor pharmacology laboratories
• Metabolic and endocrine research groups
• Cell biology laboratories working with class B GPCR signalling
• Peptide chemistry and analogue-design research groups
• Analytical laboratories characterising large modified peptides
• Academic and educational research institutions
• Biotechnology and pharmaceutical research organisations
• Contract research organisations

The product is not intended for personal experimentation, self-administration, human consumption, veterinary use, weight management, metabolic self-treatment or medical treatment of any kind.

The areas below describe experimental use of this compound. They are descriptions of research activity, not statements of outcomes attributable to this or any other supplied preparation.

Multi-Receptor Agonist Pharmacology. GLP-3RTA is studied as a reference example of unimolecular polypharmacology — a single peptide engineered for balanced activity across three related class B G-protein-coupled receptors. Comparative work in this area examines how one sequence can be tuned to different potencies at GIPR, GLP-1R and GCGR, and how those relative potencies are measured and reported.

Receptor Binding and Functional Assays. Reported EC₅₀ and Kᵢ values differ substantially between human and rodent receptor systems, which makes species a material variable rather than a footnote in any assay design using this compound as a ligand or comparator.

Peptide Design and Structure–Activity Research. The molecule combines several design strategies in one construct: backbone constraint through α-aminoisobutyric acid and α-methyl-leucine substitutions, N-terminal protection against DPP-4 cleavage, and lipidation for albumin binding. That makes it a useful case study in analogue design independent of any metabolic endpoint.

Lipidated Peptide Chemistry and Analytics. Synthesis, purification and characterisation of a lipid-conjugated 39-mer are non-trivial, and the compound appears in methodological work on large modified peptides — including chromatographic separation of closely related impurities and confirmation of conjugation.

Preclinical Metabolic Research. Published preclinical work has examined receptor-mediated responses in cellular and animal models. Findings in those systems describe those systems.

Each publication should be evaluated according to the exact molecular entity used, the species and receptor system, the concentration and preparation, and the endpoints measured.

Analytical documentation matters for any research material, and it matters in a particular way for a large lipidated peptide, because two of the usual reassurances carry less weight than they would elsewhere.

Purity. A reversed-phase area-percent figure reports what the method separates. On a 39-residue chain bearing a fatty diacid, the impurities most likely to be present — single-residue deletions, des-lipidated peptide, diastereomeric or incompletely deprotected species — are chemically close to the target and can co-elute or elute nearby. A high area-percent figure obtained on a method not developed to resolve those species is not the same claim as a high figure obtained on one that does. The method is the useful information.

Identity and mass. Mass spectrometry answers identity well for a molecule of this construction, and the lipid conjugation is large enough that its absence is unmistakable in a spectrum. The complication is knowing what mass to expect. Reported values for this compound differ between sources, and salt form changes the basis again. A COA is more useful when it states the observed mass alongside the theoretical value it was compared against, and when it names the CAS number the material was released against.

Researchers should assess, where applicable:

• Compound identity, the CAS number stated, and the analytical methods used to confirm it
• Reported purity and the chromatographic method behind it
• Whether the method resolves des-lipidated and deletion-sequence impurities
• Observed molecular mass and the theoretical value used for comparison
• Salt form, and whether content is expressed on a peptide or salt basis
• Lot or batch number
• Date of testing
• Formulation, vehicle and concentration
• Storage requirements specific to this preparation
• Expiration or retest information, where provided

No certification, regulatory approval or quality claim should be inferred unless it is explicitly documented by the manufacturer or a relevant regulatory authority. A general catalog statement is not a substitute for lot-specific documentation.

Storage and handling requirements should be taken from the current GLP-3RTA Spray product documentation and lot-specific instructions. The considerations below explain why a prepared solution of this particular molecule differs from a lyophilised solid, and are not a substitute for that documentation.

A prepared solution has no reconstitution step, so guidance written for dry material — moisture protection, reconstitution technique, post-reconstitution windows — does not transfer. What matters instead follows from the molecule’s amphiphilic construction. A large peptide carrying a C20 lipid tends to accumulate at surfaces and interfaces in dilute aqueous solution, so container material, fill level, headspace and handling that introduces air-liquid interface — vigorous shaking, repeated transfer — are more consequential than they would be for a small unmodified peptide. Self-association is a recognised general behaviour of lipidated peptides and is concentration- and formulation-dependent.

General laboratory considerations:

• Follow the storage conditions supplied with this specific product.
• Keep the container properly closed when not in use within an approved research workflow.
• Handle gently; avoid vigorous agitation and unnecessary transfer between containers.
• Avoid unnecessary temperature cycling.
• Protect from inappropriate temperature and from light.
• Maintain appropriate laboratory labelling and inventory records.
• Follow institutional procedures for handling research peptides.
• Do not use material beyond the stated storage period or applicable retest date without appropriate laboratory qualification.
• Consult the current documentation for product-specific requirements.

Storage guidance should not be carried over from a lyophilised presentation of this compound, from a pharmaceutical formulation, from another supplier’s material, or from another Helix Bio spray, because vehicle, concentration, container and any excipients all affect the behaviour of a lipidated peptide in solution.

Helix Bio’s website describes research materials as being supplied to laboratories and institutions in the United States, and describes tracked shipping and temperature-controlled handling within its fulfilment process.

Because shipping conditions, packaging specifications, availability and delivery requirements may change, researchers should review the current Helix Bio shipping information and product listing before ordering. Containers should be inspected on receipt and transferred to appropriate storage promptly.

Product packaging should remain appropriately labelled and handled as research material after delivery. Researchers are responsible for following applicable institutional, federal, state and local requirements governing research materials.

GLP-3RTA Spray is sold by Helix Bio for research and laboratory purposes only. It is not intended for human or veterinary consumption, self-administration, injection, weight management, diagnosis, treatment, cure, mitigation or prevention of any disease or condition.

The compound supplied under this designation is an investigational compound. It has not been approved by the U.S. Food and Drug Administration or by any other regulatory authority, for any indication, in any jurisdiction. It remains under clinical investigation by its pharmaceutical developer. The existence of a large and widely reported clinical development programme is not an approval, and it does not establish that any material sold as a research reagent is safe or effective for any purpose.

Published trial results for this compound were generated with a sponsor-manufactured pharmaceutical product, administered subcutaneously, at defined doses, to enrolled participants under clinical supervision, with manufacturing and release controls that do not apply to research materials. Those results describe that product under those conditions. They do not describe this material, this formulation or this format, and they must not be read as doing so.

GLP-3RTA is a catalog designation used to identify this research material. It is not a hormone name, not an approved product name, and not a statement of therapeutic classification.

This product is not a medicine, dietary supplement, weight-loss product or consumer wellness product. Researchers are responsible for determining whether a material is appropriate for their intended experimental application and for complying with applicable institutional and regulatory requirements.